These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11360029)

  • 1. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine.
    Spina E; Avenoso A; Facciolà G; Scordo MG; Ancione M; Madia A
    Ther Drug Monit; 2001 Jun; 23(3):223-7. PubMed ID: 11360029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma risperidone concentrations during combined treatment with sertraline.
    Spina E; D'Arrigo C; Migliardi G; Morgante L; Zoccali R; Ancione M; Madia A
    Ther Drug Monit; 2004 Aug; 26(4):386-90. PubMed ID: 15257068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients.
    Saito M; Yasui-Furukori N; Nakagami T; Furukori H; Kaneko S
    J Clin Psychopharmacol; 2005 Dec; 25(6):527-32. PubMed ID: 16282832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
    Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
    Psychopharmacology (Berl); 1999 Dec; 147(3):300-5. PubMed ID: 10639689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.
    Gunes A; Spina E; Dahl ML; Scordo MG
    Ther Drug Monit; 2008 Oct; 30(5):628-33. PubMed ID: 18708991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.
    Yasui-Furukori N; Mihara K; Kondo T; Kubota T; Iga T; Takarada Y; De Vries R; Kaneko S; Tateishi T
    J Clin Pharmacol; 2003 Feb; 43(2):122-7. PubMed ID: 12616663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risperidone plasma levels, clinical response and side-effects.
    Riedel M; Schwarz MJ; Strassnig M; Spellmann I; Müller-Arends A; Weber K; Zach J; Müller N; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2005 Aug; 255(4):261-8. PubMed ID: 15565299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia.
    Mihara K; Kondo T; Yasui-Furukori N; Suzuki A; Ishida M; Ono S; Kubota T; Iga T; Takarada Y; de Vries R; Kaneko S
    Ther Drug Monit; 2003 Jun; 25(3):287-93. PubMed ID: 12766554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction.
    Spina E; Avenoso A; Scordo MG; Ancione M; Madia A; Gatti G; Perucca E
    J Clin Psychopharmacol; 2002 Aug; 22(4):419-23. PubMed ID: 12172343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.
    Spina E; Avenoso A; Facciolà G; Salemi M; Scordo MG; Ancione M; Madia AG; Perucca E
    Psychopharmacology (Berl); 2001 Jan; 153(2):238-43. PubMed ID: 11205425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum concentrations and side effects in psychiatric patients during risperidone therapy.
    Olesen OV; Licht RW; Thomsen E; Bruun T; Viftrup JE; Linnet K
    Ther Drug Monit; 1998 Aug; 20(4):380-4. PubMed ID: 9712460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions.
    LLerena A; Berecz R; Dorado P; de la Garza CS; Norberto MJ; Cáceres M; Gutiérrez JR
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jan; 783(1):213-9. PubMed ID: 12450541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone.
    Jovanović N; Božina N; Lovrić M; Medved V; Jakovljević M; Peleš AM
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1109-17. PubMed ID: 20563569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate.
    Spina E; Avenoso A; Facciolà G; Salemi M; Scordo MG; Giacobello T; Madia AG; Perucca E
    Ther Drug Monit; 2000 Aug; 22(4):481-5. PubMed ID: 10942191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder.
    Vermeulen A; Piotrovsky V; Ludwig EA
    J Pharmacokinet Pharmacodyn; 2007 Apr; 34(2):183-206. PubMed ID: 17136449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography: application to therapeutic drug monitoring in Japanese patients with schizophrenia.
    Nagasaki T; Ohkubo T; Sugawara K; Yasui N; Furukori H; Kaneko S
    J Pharm Biomed Anal; 1999 Mar; 19(3-4):595-601. PubMed ID: 10704125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
    Jung SM; Kim KA; Cho HK; Jung IG; Park PW; Byun WT; Park JY
    Clin Pharmacol Ther; 2005 Nov; 78(5):520-8. PubMed ID: 16321618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents.
    Calarge CA; Miller del D
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):163-9. PubMed ID: 21486167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study.
    Yoshimura R; Ueda N; Nakamura J
    Neuropsychobiology; 2001; 44(3):129-33. PubMed ID: 11586052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.
    Kakihara S; Yoshimura R; Shinkai K; Matsumoto C; Goto M; Kaji K; Yamada Y; Ueda N; Ohmori O; Nakamura J
    Int Clin Psychopharmacol; 2005 Mar; 20(2):71-8. PubMed ID: 15729081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.